{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T23:16:56Z","timestamp":1768691816849,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.euroneuro.2023.02.010","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T14:44:03Z","timestamp":1677681843000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-3960","authenticated-orcid":false,"given":"Giacomo","family":"d'Andrea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Pettorruso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio Di","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Mancusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2023.02.010_bib0001","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jad.2015.02.004","article-title":"The Bipolarity Index: a clinician-rated measure of diagnostic confidence","volume":"177","author":"Aiken","year":"2015","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.euroneuro.2023.02.010_bib0002","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14740338.2022.2047928","article-title":"Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"21","author":"Bahji","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0003","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.euroneuro.2023.02.010_bib0004","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.encep.2016.02.003","article-title":"The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: a review of the literature","volume":"42","author":"Costemale-Lacoste","year":"2016","journal-title":"Encephale"},{"issue":"4","key":"10.1016\/j.euroneuro.2023.02.010_bib0005","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1213\/01.ANE.0000052513.91900.D5","article-title":"Blockade of voltage-operated neuronal and skeletal muscle sodium channels by S(+)- and R(-)-ketamine","volume":"96","author":"Haeseler","year":"2003","journal-title":"Anesth. Analg."},{"issue":"3","key":"10.1016\/j.euroneuro.2023.02.010_bib0006","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/mp.2016.99","article-title":"HCN-channel dendritic targeting requires bipartite interaction with TRIP8b and regulates antidepressant-like behavioral effects","volume":"22","author":"Han","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0007","article-title":"Comparison on the clinical features in patients with or without treatment-resistant depression: a national survey on symptomatology of depression report","volume":"319","author":"Huang","year":"2022","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.euroneuro.2023.02.010_bib0008","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jphs.2017.11.001","article-title":"Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine","volume":"135","author":"Ide","year":"2017","journal-title":"J. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.euroneuro.2023.02.010_bib0009","doi-asserted-by":"crossref","first-page":"e2836","DOI":"10.1002\/hup.2836","article-title":"Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression","volume":"37","author":"Jesus-Nunes","year":"2022","journal-title":"Hum. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2023.02.010_bib0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0269881120978398","article-title":"Repeated subcutaneous esketamine for treatment-resistant depression: impact of the degree of treatment resistance and anxiety comorbidity","volume":"35","author":"Lucchese","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0011","article-title":"Depression: EU approves expanded use of esketamine for rapid reduction of symptoms","volume":"372","author":"Mahase","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.euroneuro.2023.02.010_bib0012","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1192\/bjo.2018.36","article-title":"Defining a mood stabiliser: novel framework for research and clinical practice","volume":"4","author":"Malhi","year":"2018","journal-title":"BJPsych Open"},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0014","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0015","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jad.2017.12.062","article-title":"Is recurrence in major depressive disorder related to bipolarity and mixed features? Results from the BRIDGE-II-Mix study","volume":"229","author":"Mazzarini","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0016","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.euroneuro.2021.12.007","article-title":"When depression is difficult to treat","volume":"56","author":"McAllister-Williams","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.euroneuro.2023.02.010_bib0017","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1080\/03007995.2019.1636017","article-title":"Bipolar depression: the clinical characteristics and unmet needs of a complex disorder","volume":"35","author":"McIntyre","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"10.1016\/j.euroneuro.2023.02.010_bib0018","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bdi.12941","article-title":"The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder","volume":"22","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord."},{"issue":"2","key":"10.1016\/j.euroneuro.2023.02.010_bib0019","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0269881120954048","article-title":"The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: results from the Canadian rapid treatment center of excellence","volume":"35","author":"McIntyre","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2023.02.010_bib0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0021","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jad.2014.09.026","article-title":"The prevalence and illness characteristics of DSM-5-defined \u201cmixed feature specifier\u201d in adults with major depressive disorder and bipolar disorder: results from the international mood disorders collaborative project","volume":"172","author":"McIntyre","year":"2015","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.euroneuro.2023.02.010_bib0022","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","article-title":"Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats","volume":"210","author":"Nemeth","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113633","article-title":"The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL\/6J mice","volume":"418","author":"Rafa\u0142o-Uli\u0144ska","year":"2022","journal-title":"Behav. Brain Res."},{"issue":"5","key":"10.1016\/j.euroneuro.2023.02.010_bib0024","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.pharep.2016.05.010","article-title":"Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABAA and GABAB receptors","volume":"68","author":"Rosa","year":"2016","journal-title":"Pharmacol. Rep. PR"},{"issue":"8","key":"10.1016\/j.euroneuro.2023.02.010_bib0025","article-title":"Efficacy and safety of intranasal esketamine in treatment-resistant depression in adults: a systematic review","volume":"13","author":"Sapkota","year":"2021","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.euroneuro.2023.02.010_bib0026","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41380-021-01381-x","article-title":"A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials","volume":"27","author":"Sforzini","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104635","article-title":"Rapid treatments for depression: endocannabinoid system as a therapeutic target","volume":"137","author":"Sharafi","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology"},{"issue":"20","key":"10.1016\/j.euroneuro.2023.02.010_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012196","article-title":"Esmethadone (REL-1017) and other uncompetitive NMDAR channel blockers may improve mood disorders via modulation of synaptic kinase-mediated signaling","volume":"23","author":"Stahl","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.euroneuro.2023.02.010_bib0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1017\/S1092852917000256","article-title":"Mixed features in major depressive disorder: diagnoses and treatments","volume":"22","author":"Suppes","year":"2017","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0031","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2147\/NDT.S325000","article-title":"Intravenous ketamine infusions in treatment-resistant bipolar depression: an open-label naturalistic observational study","volume":"17","author":"Wilkowska","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0032","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.euroneuro.2021.09.005","article-title":"Glutamate modulators and beyond: a neuroscience revolution in the making","volume":"54","author":"Zarate","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.02.010_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109219","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","volume":"218","author":"Zhang","year":"2022","journal-title":"Neuropharmacology"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:05:31Z","timestamp":1760378731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X23000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":33,"alternative-id":["S0924977X23000378"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.02.010","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}